Confounders of excessive brain volume loss in schizophrenia

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 10, 2013, Pages 2418-2423

  Van Haren, N E ^a   Cahn, W ^a   Hulshoff Pol, H E ^a   Kahn, R S ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Antipsychotic medication; Brain volumes; Cannabis; Longitudinal; MRI; Outcome; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

BRAIN ATROPHY; BRAIN SIZE; CANNABIS USE; DISEASE ASSOCIATION; DRUG EFFECT; FUNCTIONAL ASSESSMENT; GRAY MATTER; HUMAN; ILLNESS TRAJECTORY; NEUROPATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SMOKING; SYMPTOM ASSESSMENT;

ANTIPSYCHOTIC MEDICATION; BRAIN VOLUMES; CANNABIS; LONGITUDINAL; MRI; OUTCOME; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; ATROPHY; BRAIN; CANNABIS; DISEASE PROGRESSION; GYRUS CINGULI; HUMANS; NERVE FIBERS, UNMYELINATED; PREFRONTAL CORTEX; PROGNOSIS; SCHIZOPHRENIA; SMOKING;

EID: 84890170084     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2012.09.006     Document Type: Review

References (73)

1. Antonova E., Sharma T., Morris R., Kumari V. The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophrenia Research 2004, 70:117-145.
2. Arango C., Breier A., McMahon R., Carpenter W.T., Buchanan R.W. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. American Journal of Psychiatry 2003, 160:1421-1427.
3. Boonstra G., van Haren N.E., Schnack H.G., Cahn W., Burger H., Boersma M., de Kroon B., Grobbee D.E., Hulshoff Pol H.E., Kahn R.S. Brain volume changes after withdrawal of atypical antipsychotics in patients with first-episode schizophrenia. Journal of Clinical Psychopharmacology 2011, 31:146-153.
4. Brody A.L., Mandelkern M.A., Jarvik M.E., Lee G.S., Smith E.C., Huang J.C., Bota R.G., Bartzokis G., London E.D. Differences between smokers and nonsmokers in regional gray matter volumes and densities. Biological Psychiatry 2004, 55:77-84.
5. Cahn W., Hulshoff Pol H.E., Lems E.B., van Haren N.E., Schnack H.G., Van Der Linden J.A., Schothorst P.F., van Engeland H., Kahn R.S. Brain volume changes in first-episode schizophrenia: a 1-year follow-up study. Archives of General Psychiatry 2002, 59:1002-1010.
6. Cahn W., van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Caspers E., Laponder D.A., Kahn R.S. Brain volume changes in the first year of illness and 5-year outcome of schizophrenia. British Journal of Psychiatry 2006, 189:381-382.
7. Chakos M.H., Lieberman J.A., Alvir J., Bilder R., Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 1995, 345:456-457.
8. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., Wu H., Kinon B., Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry 1994, 151:1430-1436.
9. Corson P.W., Nopoulos P., Miller D.D., Arndt S., Andreasen N.C. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. American Journal of Psychiatry 1999, 156:1200-1204.
10. Crespo-Facorro B., Barbadillo L., Pelayo-Teran J.M., Rodriguez-Sanchez J.M. Neuropsychological functioning and brain structure in schizophrenia. International Review of Psychiatry 2007, 19:325-336.
11. Davidson L., McGlashan T.H. The varied outcomes of schizophrenia. Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 1997, 42:34-43.
12. Davis K.L., Buchsbaum M.S., Shihabuddin L., Spiegel-Cohen J., Metzger M., Frecska E., Keefe R.S., Powchik P. Ventricular enlargement in poor-outcome schizophrenia. Biological Psychiatry 1998, 43:783-793.
13. Dazzan P., Morgan K.D., Orr K., Hutchinson G., Chitnis X., Suckling J., Fearon P., McGuire P.K., Mallett R.M., Jones P.B., Leff J., Murray R.M. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 2005, 30(4):765-774.
14. Dean B., Sundram S., Bradbury R., Scarr E., Copolov D. Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 2001, 103:9-15.
15. DeLisi L.E., Sakuma M., Ge S., Kushner M. Association of brain structural change with the heterogeneous course of schizophrenia from early childhood through five years subsequent to a first hospitalization. Psychiatry Research 1998, 84:75-88.
16. DeLisi L.E., Sakuma M., Maurizio A.M., Relja M., Hoff A.L. Cerebral ventricular change over the first 10 years after the onset of schizophrenia. Psychiatry Research 2004, 130:57-70.
17. Dorph-Petersen K.A., Pierri J.N., Perel J.M., Sun Z., Sampson A.R., Lewis D.A. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005, 30:1649-1661.
18. Eggan S.M., Lewis D.A. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cerebral Cortex 2007, 17:175-191.
19. Fenton W.S., McGlashan T.H. Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Archives of General Psychiatry 1991, 48:978-986.
20. Gallinat J., Meisenzahl E., Jacobsen L.K., Kalus P., Bierbrauer J., Kienast T., Witthaus H., Leopold K., Seifert F., Schubert F., Staedtgen M. Smoking and structural brain deficits: a volumetric MR investigation. European Journal of Neuroscience 2006, 24:1744-1750.
21. Giedd J.N., Jeffries N.O., Blumenthal J., Castellanos F.X., Vaituzis A.C., Fernandez T., Hamburger S.D., Liu H., Nelson J., Bedwell J., Tran L., Lenane M., Nicolson R., Rapoport J.L. Childhood-onset schizophrenia: progressive brain changes during adolescence. Biological Psychiatry 1999, 46:892-898.
22. Glass M., Dragunow M., Faull R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 1997, 77:299-318.
23. Gur R.E., Cowell P., Turetsky B.I., Gallacher F., Cannon T., Bilker W., Gur R.C. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Archives of General Psychiatry 1998, 55:145-152.
24. Ho B.C., Andreasen N.C., Nopoulos P., Arndt S., Magnotta V., Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Archives of General Psychiatry 2003, 60:585-594.
25. Höistad M., Segal D., Takahashi N., Sakurai T., Buxbaum J.D., Hof P.R. Linking white and grey matter in schizophrenia: oligodendrocyte and neuron pathology in the prefrontal cortex. Frontiers in Neuroanatomy 2009, 3:9.
26. Hulshoff Pol H.E., Kahn R.S. What happens after the first episode? A review of progressive brain changes in chronically ill patients with schizophrenia. Schizophrenia Bulletin 2008, 34:354-366.
27. Hulshoff Pol H.E., Schnack H.G., Bertens M.G., van Haren N.E., van der Tweel I., Staal W.G., Baare W.F., Kahn R.S. Volume changes in gray matter in patients with schizophrenia. American Journal of Psychiatry 2002, 159:244-250.
28. Hulshoff Pol H.E., Schnack H.G., Mandl R.C., Cahn W., Collins D.L., Evans A.C., Kahn R.S. Focal white matter density changes in schizophrenia: reduced inter-hemispheric connectivity. Neuroimage 2004, 21:27-35.
29. Hulshoff Pol H.E., Schnack H.G., Mandl R.C., van Haren N.E., Koning H., Collins D.L., Evans A.C., Kahn R.S. Focal gray matter density changes in schizophrenia. Archives of General Psychiatry 2001, 58:1118-1125.
30. Iversen L. Cannabis and the brain. Brain 2003, 126:1252-1270.
31. Kanaan R.A., Kim J.S., Kaufmann W.E., Pearlson G.D., Barker G.J., McGuire P.K. Diffusion tensor imaging in schizophrenia. Biological Psychiatry 2005, 58(12):921-929.
32. Kasai K., Shenton M.E., Salisbury D.F., Hirayasu Y., Lee C.U., Ciszewski A.A., Yurgelun-Todd D., Kikinis R., Jolesz F.A., McCarley R.W. Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia. American Journal of Psychiatry 2003, 160:156-164.
33. Kasai K., Shenton M.E., Salisbury D.F., Hirayasu Y., Onitsuka T., Spencer M.H., Yurgelun-Todd D.A., Kikinis R., Jolesz F.A., McCarley R.W. Progressive decrease of left Heschl gyrus and planum temporale gray matter volume in first-episode schizophrenia: a longitudinal magnetic resonance imaging study. Archives of General Psychiatry 2003, 60:766-775.
34. Kempton M.J., Stahl D., Williams S.C., DeLisi L.E. Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies. Schizophrenia Research 2010, 120:54-62.
35. Keshavan M.S., Bagwell W.W., Haas G.L., Sweeney J.A., Schooler N.R., Pettegrew J.W. Changes in caudate volume with neuroleptic treatment [letter]. Lancet 1994, 344:1434.
36. Koethe D., Giuffrida A., Schreiber D., Hellmich M., Schultze-Lutter F., Ruhrmann S., Klosterkotter J., Piomelli D., Leweke F.M. Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis. British Journal of Psychiatry 2009, 194:371-372.
37. Konopaske G.T., Dorph-Petersen K.A., Pierri J.N., Wu Q., Sampson A.R., Lewis D.A. Effect of chronic exposure to antipsychotic medication on cell numbers in the parietal cortex of macaque monkeys. Neuropsychopharmacology 2007, 32:1216-1223.
38. Konrad A., Winterer G. Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon?. Schizophrenia Bulletin 2008, 34(1):72-92.
39. Kubicki M., McCarley R., Westin C.F., Park H.J., Maier S., Kikinis R., Jolesz F.A., Shenton M.E. A review of diffusion tensor imaging studies in schizophrenia. Journal of Psychiatric Research 2007, 41(1-2):15-30.
40. Lasser K., Boyd J.W., Woolhandler S., Himmelstein D.U., McCormick D., Bor D.H. Smoking and mental illness: a population-based prevalence study. Journal of the American Medical Association 2000, 284:2606-2610.
41. Lenroot R.K., Giedd J.N. Brain development in children and adolescents: insights from anatomical magnetic resonance imaging. Neuroscience and Biobehavioral Reviews 2006, 30(6):718-729.
42. Leonard B.E., Schwarz M., Myint A.M. The metabolic syndrome in schizophrenia: is inflammation a contributing cause?. Journal of Psychopharmacology 2012, 26(5 Suppl.):33-41.
43. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 1999, 10:1665-1669.
44. Leweke F.M., Giuffrida A., Koethe D., Schreiber D., Nolden B.M., Kranaster L., Neatby M.A., Schneider M., Gerth C.W., Hellmich M., Klosterkotter J., Piomelli D. Anandamide levels in cerebrospinal fluid of first-episode schizophrenic patients: impact of cannabis use. Schizophrenia Research 2007, 94:29-36.
45. Lieberman J., Chakos M., Wu H., Alvir J., Hoffman E., Robinson D., Bilder R. Longitudinal study of brain morphology in first episode schizophrenia. Biological Psychiatry 2001, 49:487-499.
46. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry 2005, 62:361-370.
47. Mathalon D.H., Sullivan E.V., Lim K.O., Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Archives of General Psychiatry 2001, 58:148-157.
48. McGlashan T.H. A selective review of recent North American long-term followup studies of schizophrenia. Schizophrenia Bulletin 1988, 14:515-542.
49. Mondelli V., Cattaneo A., Belvederi Murri M., Di Forti M., Handley R., Hepgul N., Miorelli A., Navari S., Papadopoulos A.S., Aitchison K.J., Morgan C., Murray R.M., Dazzan P., Pariante C.M. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. Journal of Clinical Psychiatry 2011, 72(12):1677-1684.
50. Olabi B., Ellison-Wright I., McIntosh A.M., Wood S.J., Bullmore E., Lawrie S.M. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biological Psychiatry 2011, 70:88-96.
51. Pantelis C., Yucel M., Wood S.J., Velakoulis D., Sun D., Berger G., Stuart G.W., Yung A., Phillips L., McGorry P.D. Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophrenia Bulletin 2005, 31:672-696.
52. Paus T., Collins D.L., Evans A.C., Leonard G., Pike B., Zijdenbos A. Maturation of white matter in the human brain: a review of magnetic resonance studies. Brain Research Bulletin 2001, 54(3):255-266.
53. Poirier M.F., Canceil O., Bayle F., Millet B., Bourdel M.C., Moatti C., Olie J.P., Attar-Levy D. Prevalence of smoking in psychiatric patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002, 26:529-537.
54. Puri B.K., Hutton S.B., Saeed N., Oatridge A., Hajnal J.V., Duncan L., Chapman M.J., Barnes T.R., Bydder G.M., Joyce E.M. A serial longitudinal quantitative MRI study of cerebral changes in first-episode schizophrenia using image segmentation and subvoxel registration. Psychiatry Research 2001, 106L:141-150.
55. Rais M., Cahn W., Van Haren N.E., Schnack H., Caspers E., Hulshoff Pol H.E., Kahn R.S. Excessive brain volume loss over time in cannabis-using first-episode schizophrenia patients. American Journal of Psychiatry 2008, 165:490-496.
56. Rais M., van Haren N.E., Cahn W., Schnack H.G., Lepage C., Collins L., Evans A.C., Hulshoff Pol H.E., Kahn R.S. Cannabis use and progressive cortical thickness loss in areas rich in CB1 receptors during the first five years of schizophrenia. European Neuropsychopharmacology 2010, 20:855-865.
57. Scharpff Hirngewicht und Psychose. Archiv fur Psychiatrie und Nervenkrankheiten 1912, 49:242-252.
58. Scheepers F.E., de Wied C.C., Hulshoff Pol H.E., van de Flier W., Van Der Linden J.A., Kahn R.S. The effect of clozapine on caudate nucleus volume in schizophrenic patients previously treated with typical antipsychotics. Neuropsychopharmacology 2001, 24:47-54.
59. Schmitt A., Weber S., Jatzko A., Braus D.F., Henn F.A. Hippocampal volume and cell proliferation after acute and chronic clozapine or haloperidol treatment. Journal of Neural Transmission 2004, 111(1):91-100.
60. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophrenia Research 2001, 49:1-52.
61. Smieskova R., Fusar-Poli P., Allen P., Bendfeldt K., Stieglitz R.D., Drewe J., Radue E.W., McGuire P.K., Riecher-Rossler A., Borgwardt S.J. Neuroimaging predictors of transition to psychosis-a systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews 2010, 34:1207-1222.
62. Sowell E.R., Peterson B.S., Thompson P.M., Welcome S.E., Henkenius A.L., Toga A.W. Mapping cortical change across the human life span. Nature Neuroscience 2003, 6:309-315.
63. Thompson P.M., Bartzokis G., Hayashi K.M., Klunder A.D., Lu P.H., Edwards N., Hong M.S., Yu M., Geaga J.A., Toga A.W., Charles C., Perkins D.O., McEvoy J., Hamer R.M., Tohen M., Tollefson G.D., Lieberman J.A. Time-lapse mapping of cortical changes in schizophrenia with different treatments. Cerebral Cortex 2009, 19:1107-1123.
64. Van Haren N.E., Cahn W., Hulshoff Pol H.E., Schnack H.G., Caspers E., Lemstra A., Sitskoorn M.M., Wiersma D., Van Den Bosch R.J., Dingemans P.M., Schene A.H., Kahn R.S. Brain volumes as predictor of outcome in recent-onset schizophrenia: a multi-center MRI study. Schizophrenia Research 2003, 64:41-52.
65. Van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Brans R., Carati I., Rais M., Kahn R.S. Progressive brain volume loss in schizophrenia over the course of the illness: evidence of maturational abnormalities in early adulthood. Biological Psychiatry 2008, 63:106-113.
66. Van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Mandl R.C., Collins D.L., Evans A.C., Kahn R.S. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007, 32:2057-2066.
67. Van Haren N.E., Schnack H.G., Cahn W., Van Den Heuvel M.P., Lepage C., Collins L., Evans A.C., Hulshoff Pol H.E., Kahn R.S. Changes in cortical thickness during the course of illness in schizophrenia. Archives of General Psychiatry 2011, 68:871-880.
68. Van Os J., Fahy T.A., Jones P., Harvey I., Lewis S., Williams M., Toone B., Murray R. Increased intracerebral cerebrospinal fluid spaces predict unemployment and negative symptoms in psychotic illness. A prospective study. British Journal of Psychiatry 1995, 166:750-758.
69. Vernon A.C., Natesan S., Modo M., Kapur S. Effect of chronic antipsychotic treatment on brain structure: a serial magnetic resonance imaging study with ex vivo and postmortem confirmation. Biological Psychiatry 2011, 69(10):936-944.
70. Wassink T.H., Andreasen N.C., Nopoulos P., Flaum M. Cerebellar morphology as a predictor of symptom and psychosocial outcome in schizophrenia. Biological Psychiatry 1999, 45:41-48.
71. Wood S.J., Velakoulis D., Smith D.J., Bond D., Stuart G.W., McGorry P.D., Brewer W.J., Bridle N., Eritaia J., Desmond P., Singh B., Copolov D., Pantelis C. A longitudinal study of hippocampal volume in first episode psychosis and chronic schizophrenia. Schizophrenia Research 2001, 52:37-46.
72. Wright I.C., Rabe-Hesketh S., Woodruff P.W., David A.S., Murray R.M., Bullmore E.T. Meta-analysis of regional brain volumes in schizophrenia. American Journal of Psychiatry 2000, 157:16-25.
73. Zavitsanou K., Garrick T., Huang X.F. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2004, 28:355-360.